Diagnosis and management of sensory polyneuropathy

被引:47
作者
Gwathmey, Kelly Graham [1 ]
Pearson, Kathleen T. [1 ]
机构
[1] Virginia Commonwealth Univ, Dept Neurol, 1101 E Marshall St,POB 980599, Richmond, VA 23298 USA
来源
BMJ-BRITISH MEDICAL JOURNAL | 2019年 / 365卷
关键词
SMALL-FIBER NEUROPATHY; INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ANTI-HU; GLUCOSE-TOLERANCE; PERIPHERAL NEUROPATHIES; DIABETIC-NEUROPATHY; METABOLIC SYNDROME; CLINICAL-FEATURES; SJOGRENS-SYNDROME; NERVE DENSITY;
D O I
10.1136/bmj.l1108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sensory polyneuropathies, which are caused by dysfunction of peripheral sensory nerve fibers, are a heterogeneous group of disorders that range from the common diabetic neuropathy to the rare sensory neuronopathies. The presenting symptoms, acuity, time course, severity, and subsequent morbidity vary and depend on the type offiber that is affected and the underlying cause. Damage to small thinly myelinated and unmyelinated nerve fibers results in neuropathic pain, whereas damage to large myelinated sensory afferents results in proprioceptive deficits and ataxia. The causes of these disorders are diverse and include metabolic, toxic, infectious, inflammatory, autoimmune, and genetic conditions. Idiopathic sensory polyneuropathies are common although they should be considered a diagnosis of exclusion. The diagnostic evaluation involves electrophysiologic testing including nerve conduction studies, histopathologic analysis of nerve tissue, serum studies, and sometimes autonomic testing and cerebrospinal fluid analysis. The treatment of these diseases depends on the underlying cause and may include immunotherapy, mitigation of riskfactors, symptomatic treatment, and gene therapy, such as the recently developed RNA interference and antisense oligonucleotide therapies for transthyretin familial amyloid polyneuropathy. Many of these disorders have no directed treatment, in which case management remains symptomatic and supportive. More research is needed into the underlying pathophysiology of nerve damage in these polyneuropathies to guide advances in treatment.
引用
收藏
页数:23
相关论文
共 270 条
[31]   Paraneoplastic Anti-HU Syndrome Associated with Uterine Tumor [J].
Cote-Mantha, Evelyne ;
Savard, Martin .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2012, 39 (02) :254-255
[32]  
Cowley A, 2011, BMJ CASE REP, DOI [10.1136/bcr.04.2011.4077, DOI 10.1136/BCR.04.2011.4077]
[33]   Sarcoidosis in Black Women in the United States Data From the Black Women's Health Study [J].
Cozier, Yvette C. ;
Berman, Jeffrey S. ;
Palmer, Julie R. ;
Boggs, Deborah A. ;
Serlin, David M. ;
Rosenberg, Lynn .
CHEST, 2011, 139 (01) :144-150
[34]   Recommendations for the clinical use of somatosensory-evoked potentials [J].
Cruccu, G. ;
Aminoff, M. J. ;
Curio, G. ;
Guerit, J. M. ;
Kakigi, R. ;
Mauguiere, F. ;
Rossini, P. M. ;
Treede, R. -D. ;
Garcia-Larrea, L. .
CLINICAL NEUROPHYSIOLOGY, 2008, 119 (08) :1705-1719
[35]   Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies [J].
Dalakas, Marinos C. .
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
[36]   Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors [J].
Dalakas, Marinos C. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 377 :224-226
[37]   TREMOR AS A FEATURE OF CHRONIC RELAPSING AND DYSGAMMAGLOBULINEMIC POLYNEUROPATHIES - INCIDENCE AND MANAGEMENT [J].
DALAKAS, MC ;
TERAVAINEN, H ;
ENGEL, WK .
ARCHIVES OF NEUROLOGY, 1984, 41 (07) :711-714
[38]  
DALMAU J, 1995, CANCER, V75, P99, DOI 10.1002/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO
[39]  
2-I
[40]   Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-the LENSS study [J].
de Greef, Bianca T. A. ;
Merkies, Ingemar S. J. ;
Geerts, Margot ;
Faber, Catharina G. ;
Hoeijmakers, Janneke G. J. .
TRIALS, 2016, 17